Current Status and Future Perspectives in Differentiated Thyroid Cancer

Tae Yong Kim, Won Gu Kim, Won Bae Kim, Young Kee Shong

Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Thyroid cancer is increasing all over the world. The exact cause of this increase is still debated and there are conflicting reports. Sophisticated molecular studies suggest that environmental chemicals may have effects of thyroid carcinogenesis. The development of powerful molecular biology techniques has enabled targeted next-generation sequencing for detection of mutations in thyroid cancer, and this technique can make a specific diagnosis of thyroid cancer in cytologically indeterminate cases. The initial treatment of well-differentiated thyroid cancer (DTC) is surgery followed by radioiodine remnant ablation. However, further studies are needed to determine the optimal dosage of radioactive iodine for DTC patients with lateral neck metastasis. DTC is an indolent tumor and may cause death even decades later. Thus, long-term follow-up is mandatory. Recently, dynamic risk stratification (DRS) has begun to use stimulated thyroglobulin level at 1 year after the initial treatment and restratified the risk in accordance with the response to the initial treatment. This DRS strategy accurately predicts disease free survival and can be widely used in daily clinical settings. For the iodine refractory metastatic disease, redifferentiation therapy and targeted therapy are two promising alternative treatments. Sorafenib is the first approved agent for the treatment of progressive iodine refractory advanced thyroid cancer in Korea and may be very helpful for radioactive-refractory locally advanced or metastatic DTC. Selumetinib may be an effective redifferentiating agent and could be used within several years.

Keywords: Thyroid; Thyroid neoplasms; Diagnosis; Therapy; Prognosis

INTRODUCTION

Thyroid cancer is increasing all over the world. The exact cause of this increase is still debated and there are conflicting reports [1]. The widespread use of ultrasonography (US) which can detect small-sized thyroid cancer is a likely factor. Some researchers insist that the increased incidence of thyroid cancer is not real, but just reflects increased detection of small indolent cancers from large asymptomatic reservoirs since the cancer specific mortality rate is stationary [2]. The increased use of US and guided aspirations have contributed to increased detection of small impalpable thyroid cancers in asymptomatic patients. Routine check-up procedures have been blamed for the widespread use of US. Recently, an elegant epidemiological study in the United States revealed that only about half of this increase is due to the increased use of US, while the remaining half may be a true increase in cancer [3,4]. Also noteworthy is the finding that thyroid cancer incidence is sharply increasing in children, adolescents and young adults. Not only small-sized cancers, but also large-sized cancers (over 2 cm) have sharply increased, and this increasing trend for larger tumors rules out diagnostic scrutiny as the only explanation for...
ETIOLOGY

While we still do not know the exact cause of cancer, carcinogenesis depends on genetic predisposition and environmental stimuli. It is highly unlikely that human genetic trait changes over the last several decades are responsible for the increased incidence of cancer, which may be due to some unknown environmental changes, including radiation, chemical carcinogens, and dietary changes. Chronic inflammation may also cause cancer in general. Hashimoto thyroiditis is associated with increased incidence of papillary thyroid carcinoma (PTC), but may have a protective role [6]. Many groups including ours have provided observational data on the association of obesity and thyroid cancers [7,8]. A recent comprehensive review suggested that there are five important issues in explaining this connection, including thyroid hormones, insulin resistance, adipokines, inflammation, and sexual hormones [9].

PATHOGENESIS

Through a sophisticated molecular study, it has been documented that increases in thyroid cancer over the last four decades were accompanied by a high frequency of BRAF mutations and a sharp increase in Ras mutations. RET/PTC rearrangement is decreasing slowly [10]. These studies showed that there was a decrease in classic PTC and an increase in the follicular variant PTC. The proportion of tumors with a BRAF mutation was stable, but increased from 50% to 77% within classic PTCs. The proportion of tumors with a Ras mutation increased sharply, especially within follicular pattern tumors. Most radiation induced thyroid tumors are PTC and they are characterized by RET/PTC rearrangement. Sporadic PTC has a BRAF point mutation [11]. The decreasing frequency of RET/PTC rearrangement suggests that recent increases in thyroid cancer are likely not due to ionizing radiation exposure. The increase in frequency of the Ras mutation in follicular patterned tumors suggests that environmental chemicals may have carcinogenic effects. It is interesting that the BRAF mutation in classic PTC increased. The BRAF mutation is associated with high iodine intake [12] and with volcanic areas where many elements such as boron, iron, manganese, and vanadium in drinking water exceed the maximum admissible concentrations [13]. Whether the recent increase in iodine intake is related is an open question.

Tumor initiation and tumor progression may be separate events. If we can find the exact mechanism for tumor progression, we may treat patients with thyroid cancer only in cases of higher risk, especially patients with thyroid papillary microcarcinoma. Several groups of researchers have found that telomerase reverse transcriptase (TERT) promoter mutations are associated with aggressive, advanced metastatic thyroid cancer [14-16]. The TERT mutation is found in about 10% of PTCs and is associated with advanced stage, distant metastases and poor outcomes, indicating it may be one of the factors related to thyroid cancer progression, as opposed to cancer initiation. If we can get sufficient information about thyroid cancer progression and initiation, we can provide tailored treatments according to gene profiles. Several new factors have recently been suggested, such as an X-linked inhibitor of the apoptosis protein and CPSF2 [17,18].

DIAGNOSIS

Fine needle aspiration cytology will remain the cornerstone of the diagnosis of thyroid nodules. However, there is substantial variability in pathologists’ cytopathologic evaluation, even after widespread adoption of the Bethesda standardized reporting system [19].

The molecular biology of development and the progression of thyroid neoplasia have been extensively studied [20]. A variety of aberrant signaling in thyroid cancer has been reported and explains much about thyroid carcinogenesis [21-23]. The development of powerful molecular biology techniques enabled targeted next-generation sequencing for detection of mutations in thyroid cancer [24]. Almost all the mutations are found with this method and the technique is applied for fine needle aspiration samples and can detect cancers even with indeterminate cytology. This technique may render the sophisticated gene expression profile using RNA obsolete [25] and can make a specific diagnosis of thyroid cancer in cytologically indeterminate cases.

Molecular studies using DNA mutation profiles (specific) may replace the former gene expression profiles using RNA (sensitive). US-guided core needle biopsy was re-introduced by several group for diagnosis and management of thyroid nodules with indeterminate cytology [26]. Core needle biopsy may be useful in some indeterminate cases without much expense.
TREATMENT FOCUSED ON INITIAL RADIOACTIVE IODINE TREATMENT

The initial treatment of well-differentiated thyroid carcinoma (DTC) has been surgery followed by radioiodine remnant ablation. Improvement in surgical techniques and the use of radioiodine for intermediate to high-risk thyroid cancer patients has further improved survival rates. There are many controversies regarding surgical extent, indication for radioactive iodine remnant ablation (RRA), and the appropriate amount and preparation of RRA. Debates for the extent of surgery are above this review and we will focus on radioiodine administration.

Well-known poor prognostic factors for DTC are old age, large primary tumor size, extrathyroidal extension, nodal metastasis, and distant metastases [27]. Some reports have suggested that male sex and certain subcategorical pathologies could be other poor prognostic parameters [28]. Various tumor staging systems including the pTNM system are based upon the clinical and pathological findings at the initial treatment. They can predict patients’ outcome and further therapy is usually based on the stage of the tumor. Most experts recommend using the pTNM staging system [29], but this system was developed to predict survival, not persistent and/or recurrent disease. The American Thyroid Association (ATA) has proposed the following ATA risk classification for predicting recurrence [29]: high: patients with distant metastasis, gross invasion into surrounding tissue, or gross remnants after surgery; and intermediate: neck node metastasis, extracervical uptake after radioiodine treatment, or aggressive pathology (tall cells, columnar cells, insular cancer, Hurthle cell carcinoma, follicular carcinoma, or vascular invasion). Patients with lateral neck metastasis have a greater chance of distant metastasis [30,31] and/or death [27,32] than those with central neck metastasis. The limitation of the ATA risk classification is that both patients with only central neck lymph node metastasis and those with lateral neck lymph node metastasis are regarded as same intermediate risk.

RRA after thyroidectomy is known to be very useful to eliminate microscopic residual disease after operation [29,33]. RRAs are recommended to those patients with intermediate to high-risk. The role of RRA for those with low-risk is questionable, because most of those patients can be cured by surgery alone. Thus, in low-risk patients, low-dose iodine may be enough for ablate remnant [34-36]. Moreover, recombinant human thyrotropin may be used as well as thyroid hormone withdrawal, with comparable efficacy for preparation of the patients [37,38]. In low-risk patients, recombinant human thyrotropin aided low-dose ablation might be enough to avoid various complications from high-dose radioiodine.

The dosage of radioiodine used for remnant ablation after surgery might impact the prognosis of patients. However, many reports have showed that there were no significant differences between a low-dose (30 mCi) and a high-dose (100 mCi) for patients with intermediate risk [39,40]. Two large scaled prospective trials, one from France (the ESTIMABL study) and the other from UK (the HiLo trial), were performed to compare two different dosages of RRA for DTC patients with low- to intermediate-risk [37,38], and concluded that a low-dose is not inferior to a high-dose to achieve successful ablation. The ESTIMABL study was a multi-center large-scale randomized study recruiting a large number of low-risk DTC patients [37]. Thirty percent of patients enrolled were pathological T2N0 and another 10% were pathological T2N0. Thus, almost forty percent of patients had intrathyroidal DTC without any pathological evidence of neck node metastasis, and could be cured by surgery alone. Another 40% of patients had pT1Nx disease, and these patients did not receive prophylactic neck dissection. The most striking finding was that 43% of patients with negative thyroglobulin (Tg) antibody at the time of ablation showed Tg levels less than 1 ng/mL just before RRA. This finding suggests that 43% of total patients were already cured by surgery alone. Only 15% to 20% of total patients had N1 disease, but there was no data regarding sub-classification of neck node according to location, such as N1a (central neck only) or N1b (lateral neck). Thus, this study is not sufficient to conclude that low-dose radioiodine is noninferior to high-dose radioiodine for intermediate risk patients, such as DTC patients with lateral neck metastasis. The HiLo trial was also a prospective multicenter study with slightly fewer patients enrolled and showed similar results to the ESTIMABL study [38]. The spectrum of the recruited patients was wider in the HiLo trial. The ESTIMABL study recruited DTC patients with T1/T2 and N0/Nx/N1. The HiLo trial included same staged patients plus additional patients with T3 disease. Seventy-five percent of the study subjects had T1, T2 and 60% of patients had N0 disease. These low-risk patients can be cured by surgery alone, and the effect of ablation was questionable for this group. Similar to the ESTIMABL study, only 15% of patients had N1 disease and 25% of patients had Nx disease. Also, there were no differences between central and lateral neck metastasis. A meta-analysis covering nine prospectively designed...
papers including the ESTIMABL and HiLo trial was recently published [41]. This analysis showed that there was no significant difference between the low and high dosage regimen. Thus, they recommend using the low-dose regimen, because there is less chance of side effects. However, some studies enrolled a very limited number of patients with neck node metastases [37-39], and another did not describe the neck node metastasis status [42,43]. Thus, we could not obtain information regarding the optimal dosage of RRA for DTC patients with lateral neck metastasis from these pre-existing prospective studies.

Recently, postsurgical ablation with low radioactive iodine activity was shown to be comparable to high dosage in thyroid cancer patients with intermediate risk [40]. In a selected intermediate risk group of patients, a low-dose may be also enough. Sabra et al. [44] showed that a higher dosage of radioactive iodine might be required for older patients with lateral neck node metastasis. Bartenstein et al. [45] reported that high-risk DTC patients with T4 primary tumors achieve successful remnant ablation equally well using recombinant human thyroid stimulating hormone (rhTSH) or thyroid hormone withdrawal. In high-risk patients, a high-dose radioactive iodine is still necessary.

**FOLLOW-UP STRATEGIES BASED ON DYNAMIC RISK STRATIFICATION**

Thyroid cancer is an indolent tumor. Sometimes, widespread thyroid cancer may cause death even decades later. The cumulative death rate increases 5 years after initial diagnosis and continues to gradually increase for 30 years [46]. Long-term follow-up for 10 to 15 years after surgery is mandatory for thyroid cancer patients.

Tg is a large (660 kDa) glycoprotein that is produced only from thyroid follicular cells, and serves as a precursor of thyroid hormone biosynthesis. Tg is contained in thyroid follicles, but some Tg is released from the follicle probably in accordance with thyroid hormone release, and therefore some Tg is always found in the serum and Tg levels have a rough correlation with the functioning thyroid mass. When bilateral total thyroidectomy is done, especially if it is followed by radioiodine remnant ablation leaving no remaining normal thyroid tissues, Tg should be undetectable. Any detectable Tg level may suggest the presence of abnormal thyroid follicular cells, which in turn may mean recurrent/persistent DTC cells. In this regard, measurement of Tg level is the best guidance for surveillance of DTC patients for monitoring the recurrence or persistence of cancer in patients who have undergone thyroid surgery and radioiodine remnant ablation, because the only source of Tg is thyroid tissue, which may be normal or neoplastic [47,48]. Stimulated Tg (sTg) is a serum Tg measured after endogenous TSH simulation by thyroid hormone withdrawal or after exogenous rhTSH administration. Several studies have reported that serum sTg level obtained after thyroid hormone withdrawal during the first year of follow-up has a high degree of sensitivity and specificity to detect recurrent/persistent thyroid cancer [47,49]. Since Tg production by normal or abnormal (neoplastic) follicular cells is partly dependent upon thyrotropin stimulation, interpretation of the Tg level should be cautious, considering the simultaneously measured thyrotropin level [50,51].

Most of the currently used assays have functional sensitivity between 0.5 and 1.0 ng/mL (first-generation assays). First generation assays cannot differentiate the small remnant amount of thyroid tissue after surgery or small amounts of persistent or recurrent thyroid cancer tissues, and stimulation by endogenous or exogenous thyrotropin was necessary. Recently, more sensitive assays with functional sensitivity around 0.1 ng/mL have been developed (ultrasensitive Tg assays) [52]. Using these sensitive Tg assay methods, the need for thyrotropin stimulation may be reduced, at least in low-risk groups, since it has very high negative predictive value [53-55]. In low-risk patients, ultrasensitive Tg assay under thyroxine administration may replace thyrotropin-stimulated Tg measurement. However, due to insufficient positive predictive value of this ultrasensitive Tg assay method, the stimulated Tg level may be determined in intermediate- and high-risk patients [54].

For DTC, the impact of therapy is rather high, and with extensive surgery and high-dose radioactive iodine therapy, many patients have an excellent prognosis, even despite an advanced tumor stage at diagnosis. In this regard, dynamic risk stratification (DRS) at certain intervals after initial treatment may predict final outcomes, especially recurrence, more accurately [56]. Tuttle et al. [56] suggested that patients may be restratified according to stimulated Tg level at 1 year after the initial treatment, and they are in accordance with the response to the initial treatment. They divided patients into excellent, acceptable, biochemically incomplete and structurally incomplete response groups. In the first three groups, no evidence of disease was found with imaging studies, but their stimulated Tg levels were below 1 ng/mL, between 1 and 10 ng/mL, and over 10 ng/mL, respectively. If the suppressed Tg level is above 1 ng/mL or the stimulated Tg level rises, the pa-
tient belongs to the biochemical incomplete response group. If a suspicious disease is found by any imaging study, the patient belongs to the structural incomplete response. This DRS strategy more accurately predicts disease-free survival, since the impact of treatment is included in the classification system. We modified this system and included the titers of Tg antibody [57]. In the low- and intermediate-risk groups, all recurrence was found within 8 years after surgery with modern techniques, rendering very long term meticulous follow-up rather simple [58].

ALTERNATIVE THERAPY FOR RADIOACTIVE IODINE REFRACTORY DTC

Radioiodine treatment is a very effective treatment for metastasis cancer from DTC. However, only two thirds of patients with metastases show substantial radioactive iodine uptake, and only 42% of them are cured [59]. Thus various alternative therapies have been tried in radioiodine refractory DTC. These can be divided into two major categories: redifferentiation therapy and targeted therapy. There have been many clinical trials with regard to these therapies.

Retinoic acid (RA) binds to nuclear receptors designated as RA receptors or retinoid X receptors, and these bound complexes induce expression of specific retinoid-target genes by functioning on the RA-responsive element that is located in the promoter sites. In thyroid cancers, RA induces redifferentiation of cancer cells and expression of the NIS gene. As a result, radioiodine uptake of tumors and serum Tg level are expected to increase with RA treatment [60,61]. However, the results are currently somewhat limited. Recently, there is another approach using selumetinib, an MEK inhibitor, as a redifferentiating agent of radioiodine refractory metastatic disease. The first pilot study showed very promising results, and such a treatment modality will probably be clinically available within several years [62].

DTC is usually associated with genetic alterations in signaling pathways, which are responsible for cell growth and transformation. Of these genetic mutations, RET/PTC and BRAF mutations have been studied as therapeutic targets in advanced PTCs. The genetic abnormalities that involve RET proto-oncogene via rearrangements leading to the formation of chimeric protein kinases results in constitutive activation tyrosine kinase pathways in thyroid epithelial cells. DTCs frequently show abnormal activation of Ras-Raf pathways by the mutation of Ras and BRAF proteins. Point mutations leading to BRAF signaling independent of binding to Ras have been reported in 35% to 70% of PTCs. In addition, vascular endothelial growth factor (VEGF) and other angiogenesis factors secreted by tumors act on VEGF receptors and platelet-derived growth factor receptors, which are vascular endothelial cell receptor tyrosine kinases, and angiogenesis is promoted as a result. All of these findings are plausible for clinical trials of kinase inhibitors, which inhibit such growth signals in tumor cells and angiogenesis signals in vascular endothelial cells.

There have been around 10 reported phase two studies of antiangiogenic agents in DTC using axitinib [63], motesanib [64], pazopanib [65], sunitinib [66], vandetanib [67], and sorafenib [68-72]. Recently, the first phase 3 study for radioactive-refractory locally advanced or metastatic DTC using sorafenib were published. Sorafenib is the first approved agent for the treatment of progressive iodine refractory advanced thyroid cancer in Korea and may be very helpful for those patients [73].

CONCLUSIONS

Thyroid cancer is increasing all over the world and the exact cause of this increase is still debated. The development of powerful molecular biology techniques has enabled a specific diagnosis of thyroid cancer in cytologically indeterminate cases. The initial treatment of well-differentiated thyroid cancer is surgery followed by RRA and further studies are needed to determine the optimal dosage of radioactive iodine for DTC patients with intermediate to high risk. DRS have begun to re-stratified the risk in accordance with the response to the initial treatment. For the iodine refractory metastatic disease, redifferentiation therapy and targeted therapy are two promising alternative treatments. Sorafenib is the first approved agent for the treatment of progressive iodine refractory advanced thyroid cancer in Korea and may be very helpful for radioactivity-refractory locally advanced or metastatic DTC.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R. Increasing incidence of thyroid cancer: controversies explored.
2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-22.

3. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801-7.

4. Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrason. Thyroid 2014;24:472-9.

5. Vergamini LB, Frazier AL, Abrantes FL, Ribeiro KB, Rodriguez-Galindo C. Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. J Pediatr 2014;164:1481-5.

6. Latina A, Gullo D, Trimarchi F, Benvenga S. Hashimoto’s thyroiditis: similar and dissimilar characteristics in neighboring areas. Possible implications for the epidemiology of thyroid cancer. PLoS One 2013;8:e55450.

7. Han JM, Kim TY, Jeon MJ, Yim JH, Kim WG, Song DE, Hong SJ, Bae SJ, Kim HK, Shin MH, Shong YK, Kim WB. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013;168:879-86.

8. Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R, Goudeva L, Mueller JA, Nerlich A, Pellegrini G, Reiners C, Romei C, Schwab R, Abend M, Sturgis E. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid 2014;24:966-74.

9. Marcello MA, Cunha LL, Batista FA, Ward LS. Obesity and thyroid cancer. Endocr Relat Cancer. Epub 2014 Apr 16. DOI: http://dx.doi.org/10.1530/ERC-14-0070.

10. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, Nikiforov YE. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014;99:E276-85.

11. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandini M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004;209:1-6.

12. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009;94:1612-7.

13. Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S, Dardanoni G, Frasca F, Malandrino P, Vermiglio F, Previtera DM, D’Azzo G, Trimarchi F, Vigneri R. Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst 2009;101:1575-83.

14. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013;98:E1562-6.

15. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603-10.

16. Melo M, Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Cavalheiro M, Maximo V, Sobrinho-Simoes M, Soares P. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014;99:E754-65.

17. Kim TY, Jeon MJ, Kim TY, Yoon JH, Kim WG, Song DE, Hong SJ, Bae SJ, Kim HK, Shin MH, Shong YK, Kim WB. Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population. Thyroid 2014;24:689-94.

18. Nilubol N, Boufraqech M, Zhang L, Kebebew E. Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease. J Clin Endocrinol Metab 2014;99:E1173-82.

19. Cibas ES, Baloch ZW, Fellegrina G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Klos RT, Lanman RB, Mandel SJ, Sindy N, Steward DL, Zeiger MA, Haugen BR, Alexander EK. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med 2013;159:325-32.

20. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013;34:439-55.

21. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21 Suppl 2:S37-43.

22. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62.
23. Wang HM, HuangYW, HuangJS, WangCH, KokVC, HungCM, ChenHM, TzenCY. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol 2007;14:3011-8.

24. Nikiforova MN, WaldAI, RoyS, DursoMB, NikiforovYE. Targeted next-generation sequencing panel (Thyro-Seq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013;98:E1852-60.

25. AlexanderEK, KennedyGC, BalochZW, CibasES, Chu-dovaD, DiggansJ, FriedmanL, KloorRT, LiVolisiVA, MandelSJ, RaabSS, RosaiJ, StewardDL, WalshPS, WildeJL, ZeigerMA, LammanRB, HaugenBR. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367:705-15.

26. ChoiYJ, BaekJH, HaEJ, LimHK, LeeJH, KimJK, SongDE, ShongYK, HongSJ. Differences in risk of malignancy and management recommendations in subcategories of thyroid nodules with atypia of undetermined significance or follicular lesion of undetermined significance: the role of ultrasound-guided core-needle biopsy. Thyroid 2014;24:494-501.

27. VerburgFA, MaderU, TanaseK, ThiesED, DiesslS, BuckAK, LusterM, ReinersC. Life expectancy is reduced in differentiated thyroid cancer patients \( \geq 45 \) years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 2013;98:172-80.

28. YangL, ShenW, SakamotoN. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol 2013;31:468-74.

29. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Differentiated Thyroid C, CooperDS, DohertyGM, HaugenBR, KloorRT, LeeSL, MandelSJ, MazarferriEL, MelverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.

30. MachensA, DralleH. Correlation between the number of lymph node metastases and lung metastasis in papillary thyroid cancer. J Clin Endocrinol Metab 2012;97:4375-82.

31. JeonMJ, KimTY, KimWG, HanJM, JangEK, ChoiYM, SongDE, YoonJH, ChungKW, HongSJ, ShongYK, KimWB. Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma. Clin Endocrinol (Oxf). Epub 2014 Apr 18. DOI: http://dx.doi.org/10.1111/cen.12463.

32. SmithVA, SessionsRB, LentschEJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol 2012;106:357-62.

33. PaciniF, SchlumbergerM, DralleH, EliseiR, SmitJW, WiersingaW, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.

34. SchwartzC, BonnetainF, DabakuyoS, GauthierM, CueffA, FieffeS, PochartJM, CochetI, CrevisyE, DalacA, Pat-pathanassiouD, ToubauEM. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012;97:1526-35.

35. KruijffS, AnissAM, ChenP, SidhuSB, DelbridgeLW, RobinsonB, Clifton-BlighRJ, RoachP, GillAJ, LearoydD, SywakMS. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma. Surgery 2013;154:1337-44.

36. WelshL, PowellC, PrattB, HarringtonK, NuttingC, HarmerC, NewboldK. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab 2013;98:1819-25.

37. SchlumbergerM, CatargiB, BorgetI, DeandreisD, Zer-doudS, BridjiB, BardetS, LeenhardtL, BastieD, Schvar-tzC, VeraP, MorelO, BenisyS, BournaudC, BonichonF, DejaxC, ToubertME, LebouleuxS, RicardM, Ben-hamouE; Tumeurs de la Thyroïde Refractaires Network. The impact of central lymph node involvement on survival in centrally resected differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.

38. WiersingaW; European Thyroid Cancer Taskforce. European guidelines for recombinant thyrotropin-stimulated postoperative thy-
roid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6.

40. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, Belardini V, Brianzoni E, Pacini F. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol 2013;169:23-9.

41. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, Wang H. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab 2013;98:1353-60.

42. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.

43. Fallahi B, Beiki D, Takavara A, Fard-Esfahani A, Gilani KA, Saghari M, Eftekhar M. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun 2012;33:275-82.

44. Sabra M, Grewal R, Ghossein RM, Tuttle RMM. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid 2014;24:1088-95.

45. Bartenstein P, Calabuig EC, Maini CL, Mazzarotto R, Muros de Fuentes MA, Petrich T, Rodrigues FJ, Vallejo Casas JA, Vianello F, Basso M, Balaguer MG, Haug A, Monari F, Vano RS, Sciuto R, Magner J. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid 2014;24:480-7.

46. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7.

47. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Lademson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.

48. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435-41.

49. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, Kievit J. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74.

50. Schlumberger M, Charbord P, Fragu P, Lumbroso J, Parmentier C, Tubiana M. Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. J Clin Endocrinol Metab 1980;51:513-9.

51. Schneider AB, Line BR, Goldman JM, Robbins J. Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 1981;53:1199-206.

52. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010;20:587-95.

53. Schlumberger M, Borget I, Nascimento C, Brassard M, Leboulleux S. Treatment and follow-up of low-risk patients with thyroid cancer. Nat Rev Endocrinol 2011;7:625-8.

54. Giovanella L, Treglia G, Sadeghi R, Trimболi P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014;99:440-7.

55. Giovanella L, Clark P, Chiovato L, Duntas LH, Elisei R, Feldt-Rasmussen U, Leenhardt L, Luster M, Schalin-Jantti C, Schott M, Seregni E, Rimmele H, Smit JW, Verburg FA. Diagnosis of endocrine disease: thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171:R33-46.

56. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20:1341-9.

57. Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, Chung KW, Ryu JS, Hong SJ, Shong YK, Kim WB. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2014;170:23-30.
MM, Rossi B, Ronga G, Durante C, Pacini F. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab 2008;93:3950-7.

59. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagl JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9.

60. Schmutzler C, Schmitt TL, Glaser F, Loos U, Kohrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 2002;189:145-55.

61. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, Shong YK. Redifferentiation therapy with 13-cis retinoic acids in radiodiode-resistant thyroid cancer. Endocr J 2009;56:105-12.

62. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radiodiode uptake in advanced thyroid cancer. Endoc J Med 2013;368:623-32.

63. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Torotorici M, Shalinsky DR, Luiu KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.

64. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitara L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiatied thyroid cancer. N Engl J Med 2008;359:319-42.

65. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster K, Bieber C, Tanyor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radiodiode-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72.

66. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8.

67. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gomez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012:13:897-905.

68. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22.

69. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9.

70. Hoftiijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW. Beneficial effects of sorafenib on tumor progression, but not on radiodiode uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31.

71. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.

72. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012;167:643-50.

73. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ, on behalf of the DiSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. Epub 2014 Apr 23. DOI: http://dx.doi.org/10.1016/S0140-6736(14)60421-9.